Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) and the 17th Annual WORLDSymposium™ 2021
January 26, 2021 07:00 ET
|
Freeline Therapeutics
LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
February 04, 2020 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences in February
January 31, 2020 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 31, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
February 08, 2019 07:00 ET
|
uniQure Inc.
~ Increases in FIX Activity Sustained at up to 51% of Normal, with Mean FIX of 38% of Normal at Twelve Weeks After Administration ~ ~ None of the Patients Received Factor Infusions, Reported Bleeding...
uniQure to Participate in Multiple Upcoming Industry Conferences
January 30, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 30, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...